Biosight is a clinical-stage hemato-oncology company developing innovative therapeutics which address significant unmet needs and large markets.

​

Biosight’s lead product, aspacytarabine (BST-236), is a novel antimetabolite, which provides potential advantage over standard-of-care, as demonstrated in >100 patients to date.

​

Results from a recently completed Phase 2b clinical trial, presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate that aspacytarabine monotherapy is safe and efficacious as a first-line AML therapy for patients who are unfit for intensive chemotherapy.

​

Two additional phase 2 clinical trials are currently ongoing in the US and Europe, to evaluate aspacytarabine as a monotherapy for relapsed or refractory AML and MDS. 

​

A phase 1/2 trial was recently launched, to evaluate the safety and efficacy of aspacytarabine in combination with the BCL2 inhibitor venetoclax for induction therapy of newly-diagnosed AML, followed by aspacytarabine single-agent consolidation therapy. 

​

 

Aspacytarabine is uniquely positioned to serve as a superior backbone for AML and MDS therapy, either as a single-agent or in combination with other agents